Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience

Chimeric antigen receptor (CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma and results in a unique toxicity profile, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. The hyper-inflammatory state associated with these toxicities has been suggested to increase the risk of thrombosis.
We conducted a retrospective analysis of patients treated with axicabtagene ciloleucel (axi-cel) to assess the rate of thrombosis with axi-cel therapy from the time of CAR T-cell infusion until the end of hospitalization, when performed in the inpatient setting, or up to day +30 when performed in the outpatient setting. Ninety-two (95%) of 97 patients were hospitalized during axi-cel therapy and 85 (88%) developed CRS. Fifty-five patients (57%) received concurrent anticoagulation (53 as prophylaxis). Patients with prior VTE did not have progression https://joplink.net/antigens/ or evidence of new VTE. Only 2 (2.1%) patients developed VTE. These results demonstrate a low-risk for thrombosis in axi-cel recipients.

The Protective Action of Piperlongumine Against Mycobacterial Pulmonary Tuberculosis in Its Mitigation of Inflammation and Macrophage Infiltration in Male BALB/c Mice

Introduction: Piperlongumine (PL) is a bioactive alkaloid and medicinal compound of piperamide isolated from the long pepper (Piper longum Linn). It has demonstrated bactericidal action against Mycobacterium tuberculosis (MTB), the cause of pulmonary tuberculosis; nevertheless, immunomodulatory activity had not been identified for it in MTB-triggered granulomatous inflammation. This study investigated if piperlongumine could inhibit such inflammation.
Material and methods: Mycobacterium tuberculosis strain H37Rv was subjected to a broth microdilution assay. Piperlongumine at 5, 15, and 25 μg/mL, 0.2% dimethyl sulphoxide as control or 4 μM of dexamethasone were tested in vitro on MH-S murine alveolar macrophages. BALB/c mice were orally administered PL at 50, 100 and 150 mg/kg b.w. after trehalose-6,6-dimycolate (TDM) stimulation.
Chemokine and cytokine concentrations were determined in lung supernatants. Flow cytometry and Western blot analysis were performed to determine phosphorylated spleen tyrosine kinase (Syk), c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) pathways.
Results: Piperlongumine inhibited inflammatory mediators and adherence of lymphocyte function-associated antigen 1 to MH-S cells following TDM activation. It also improved macrophage clearance of MTB. In TDM-stimulated MH-S cells, PL significantly influenced the macrophage inducible Ca2+-dependent lectin receptor (Mincle)-Syk-ERK signalling pathway. Oral dosing of PL effectively suppressed the development of pulmonary granulomas and inflammatory reactions in the TDM-elicited mouse granuloma model.

Prevalence of Toxoplasma Gondii in Retail Fresh Meat Products from Free-range Chickens in Spain

Toxoplasma gondii is one of the most prevalent zoonotic protozoan parasites worldwide and affects the vast majority of warm-blooded animal species, including humans. Postnatal infection in humans occurs through the ingestion of sporulated T. gondii oocysts or via the oral intake of parasite tissue cysts during the consumption of raw or undercooked meat. In this regard, given their high exposure to oocysts, chickens (Gallus domesticus) raised on the ground constitute a potential source of T. gondii.
Material and methods: For the first time in Spain, a survey was undertaken in commercial retail free-range poultry. A total of 50 thighs from different animals were analysed. The samples were homogenised and an acid pepsin digestion procedure was applied prior to molecular analysis. Toxoplasma gondii DNA was isolated from meat by qPCR. Two sets of primers were used for DNA amplification targeting the specific sequence of a 529 bp repeat element and another set of primers was utilised for the surface antigen protein-1 gene.

Interrelationships between amphiregulin, kisspeptin, FSH and FSH receptor in promotion of human ovarian cell functions

The aim of this study was to investigate: (1) the ability of granulosa cells to produce amphiregulin (AREG), kisspeptin (KISS) and FSH receptor (FSHR); (2) the role of AREG and KISS in the control of ovarian functions; (3) the effect of FSH and KISS on AREG; and (4) the ability of KISS to affect FSHR and to modify FSH action on AREG output by human ovarian granulosa cells. We examined: (1) time-dependent accumulation of AREG; (2) effects of AREG (0, 1, 10, 100ng/mL) and KISS (0, 1, 10, 100ng/mL) on granulosa cell functions; and (3) the effects of KISS (0, 1, 10, 100ng/mL), FSH (0, 1, 10, 100ng/mL), and their combinations on AREG release.
Viability, markers of proliferation [accumulation ofproliferating cell nuclear antigen (PCNA) cyclin B1 and sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy6-nitro)benzene sulfonic acid hydrate (XTT formazan)] and apoptosis (accumulation of bax, caspase 3 and terminal deoxynucleotidyl transferase dUTP nick-end labelling), accumulation of KISS, FSHR and steroid hormones, and AREG release were analysed by Trypan blue exclusion test, quantitative immunocytochemistry, XTT, terminal deoxynucleotidyl transferase dUTP nick-end labelling assays and enzyme-linked immunosorbent assay.
AREG promoted cell viability, proliferation and steroid hormone output, and inhibited apoptosis. KISS (1 and 10ng/mL) stimulated viability, proliferation, steroid hormone release and occurrence of FSHR and suppressed apoptosis and AREG output; KISS (100ng/mL) had the opposite effect. FSH stimulated AREG release, whilst addition of KISS reversed this FSH effect. FSH mimicked and promoted the inhibitory effect of KISS on AREG release. These results suggest an intra-ovarian production and a functional interrelationship between AREG, KISS, FSH and FSHR in direct regulation of basic ovarian cell functions.

Novel PE and APC tandems: Additional near-infrared fluorochromes for use in spectral flow cytometry

Recent advances in flow cytometry instrumentation and fluorochrome chemistries have greatly increased fluorescent conjugated antibody combinations that can be used reliably and easily in routine experiments. The Cytek Aurora flow cytometer was first released with three excitation lasers (405, 488, and 640 nm) and incorporated the latest Avalanche Photodiode (APD) technology, demonstrating significant improvement in sensitivity for fluorescent emission signals longer than 800 nm.
However, there are limited commercially available fluorochromes capable of excitation with peak emission signals beyond 800 nm. To address this gap, we engineered six new fluorochromes: PE-750, PE-800, PE-830 for the 488 nm laser and APC-750, APC-800, APC-830 for the 640 nm laser.
Utilizing the principal of fluorescence resonance energy transfer (FRET), these novel structures were created by covalently linking a protein donor dye with an organic small molecule acceptor dye. Additionally, each of these fluorochrome conjugates were shown to be compatible with fixation/permeabilization buffer reagents, and demonstrated acceptable brightness and stability when conjugated to antigen-specific monoclonal antibodies. These six novel fluorochrome reagents can increase the numbers of fluorochromes that can be used on a spectral flow cytometer.

Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis

Autoimmune and paraneoplastic encephalitides represent an increasingly recognized cause of devastating human illness as well as an emerging area of neurological injury associated with immune checkpoint inhibitors. Two groups of antibodies have been detected in affected patients. Antibodies in the first group are directed against neuronal cell surface membrane proteins and are exemplified by antibodies directed against the N-methyl-D-aspartate receptor (anti-NMDAR), found in patients with autoimmune encephalitis, and antibodies directed against the leucine-rich glioma-inactivated 1 protein (anti-LGI1), associated with faciobrachial dystonic seizures and limbic encephalitis. Antibodies in this group produce non-lethal neuronal dysfunction, and their associated conditions often respond to treatment.
  • Antibodies in the second group, as exemplified by anti-Yo antibody, found in patients with rapidly progressive cerebellar syndrome, and anti-Hu antibody, associated with encephalomyelitis, react with intracellular neuronal antigens.
  • These antibodies are characteristically found in patients with underlying malignancy, and neurological impairment is the result of neuronal death. Within the last few years, major advances have been made in understanding the pathogenesis of neurological disorders associated with antibodies against neuronal cell surface antigens.
  • In contrast, the events that lead to neuronal death in conditions associated with antibodies directed against intracellular antigens, such as anti-Yo and anti-Hu, remain poorly understood, and the respective roles of antibodies and T lymphocytes in causing neuronal injury have not been defined in an animal model.
  • In this review, we discuss current knowledge of these two groups of antibodies in terms of their discovery, how they arise, the interaction of both types of antibodies with their molecular targets, and the attempts that have been made to reproduce human neuronal injury in tissue culture models and experimental animals.
  • We then discuss the emerging area of autoimmune neuronal injury associated with immune checkpoint inhibitors and the implications of current research for the treatment of affected patients.

 

COVID-19 Antigen Rapid Test Pen (Saliva)

Panbio 2

The Rapid Response COVID-19 Antigen Rapid Test Pen (Saliva) is an in vitro immunoassay. The assay is for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from saliva samples through visual interpretation of colour development. This test is intended for professional use only.

Key Benefits:

• First and the only no-spit test dedicated to COVID-19 – Its sponge-like pen tip will collect a sufficient volume of specimen in 2 mins without the need to spit and avoiding uncomfortable nasal/throat swabbing.
• ALL IN ONE – No need to waste time setting up a workstation and handle numerous assay components. All you need is one pen that can be used comfortably in any location.

Test Principle 

Anti-SARS-CoV-2 antibodies are immobilized on the test region of the nitrocellulose membrane. Anti-SARS-CoV-2 antibodies conjugated to coloured particles are immobilized on the conjugated pad. A sample is added to the extraction buffer which is optimized to release the SARS-CoV-2 antigens from specimen. During testing, target antigens, if present in the saliva samples, will be released into the extraction buffer individually packed in the kit. Consequently, the extracted antigens will bind to anti-SARS-CoV-2 antibodies conjugated to coloured particles

As the specimen migrates along the strip by capillary action and interacts with reagents on the membrane, the complex will be captured by the anti-SARS-CoV-2 antibodies at the test region. Excess coloured particles are captured at the internal control zone. The presence of a coloured band in the test region indicates a positive result for the SARS-CoV-2 viral antigens, while its absence indicates a negative result. A coloured band at the control region serves as a procedural control, indicating that the proper volume of specimen has been added and membrane wicking is working.

 

ï¿­ INVBIO saliva alcohol screening test kit detects alcohol presence in saliva. Therefore, directly dipping the strip into alcohol alone will not provide you with an accurate reading.
ï¿­ It is very important that the test be read at exactly two minutes, The result you read 2 minutes after saturation with saliva is the accurate test result.
ï¿­Nothing should be placed into the mouth of the subject for at least 10 minutes prior to saliva collection. This includes food, drink, tobacco products or other materials.

SPECIMEN COLLECTION AND PREPARATION
ï¿­Nothing should be placed into the mouth of the subject for at least 10 minutes prior to saliva collection. This includes food, drink, tobacco products or other materials.
ï¿­ Saliva specimen can be collected in a sputum cup or a clean container, or directly applied to the reaction pad of the test strip.

PROCEDURE:
Open the foil package and remove the test strip.
Saturate the reactive pad by dipping the reaction pad into the saliva specimen collected in a cup, or saturate the reactive pad on the end of stick with saliva in mouth for 10 seconds, shake off the excess saliva.
Immediately start timer and at exactly 2 minutes, compare the reactive pad with the provided colored chart.
Results after more than 2 minutes may be not accurate.

INTERPRETATION OF RESULTS:
­ Negative: Almost no color change by comparing with the background. The negative result indicates that the BAC is less than 0.02%.
­ Positive: A distinct color developed all over the pad. The positive result indicates that the BAC is 0.02% or higher.
­ Invalid: The test should be considered invalid If only the edge of the reactive pad turned color that might be ascribed to insufficient sampling.

 

Luminex MAGPIX NATtrol

This examination was carried out to examine the results of indole-3-acetate sodium (IAA-Na) inclusion in diets on the egg manufacturing efficiency, egg high quality, intestinal tissue morphology, serum hormone ranges and biochemical parameters of Danzhou chickens to preliminarily discover the efficacy of IAA-Na as a feed additive. A complete of 192 Danzhou chickens (50 weeks previous) have been randomly assigned to 2 teams of 96. The diets for the therapy group consisted of basal diets, supplemented with IAA-Na (200 mg/kg).
The formal feeding trial lasted for 4 weeks. The outcomes confirmed that the feed supplemented with IAA-Na not solely elevated the laying charge (p < 0.05) and egg yolk ratio (0.05 < p < 0.1), but additionally considerably lowered the feed:egg ratio (p < 0.05). In addition, the dietary supplementation of IAA-Na considerably elevated the serum estradiol ranges (p < 0.05) and decreased serum alkaline phosphatase exercise (p < 0.05).
Compared with the management group, the addition of IAA-Na to the weight-reduction plan had no important impact on the intestinal tissue morphology or serum antioxidant capability of Danzhou chickens. This examination preliminarily gives proof that dietary IAA-Na can enhance laying efficiency, indicating that IAA-Na is a doubtlessly efficient feed additive for laying hens, however additional research are required earlier than arriving at particular conclusions.

Luminex MAGPIX NATtrol aimed zinc (Zn) supplementation and serum ranges of copeptin, high-sensitive C-reactive protein (hs-CRP), glycemic management, anthropometric parameters and renal operate in Zn -deficient diabetic hemodialysis patients (DHPs). This randomized, double-blind, placebo-controlled trial (RCT) was carried out on 46 DHPs with Zn-deficiency.

The Zn complement group (n = 21) acquired a 220-mg/day Zn sulfate capsule (containing 50 mg Zn), and the management group (n = 25) acquired a placebo capsule (220 mg corn starch), for eight weeks. Fasting, predialysis blood samples have been taken at baseline and after eight weeks to assess fasting blood glucose (FBG), serum insulin, copeptin, high-sensitive C-reactive protein (hs-CRP), blood urea nitrogen (BUN), creatinine (Cr) concentrations, and homoeostatic mannequin evaluation (HOMA-IR) and quantitative insulin-sensitivity verify index (QUICKI).
Compared to controls, serum copeptin (P < 0.001), hs-CRP (P < 0.001), BUN (P < 0.001), Cr (P < 0.001), Zn (P < 0.001), FBG (P < 0.001) ranges, BMI (P < 0.001), and physique weight (P < 0.001) have been considerably affected following ZnSO4 supplementation for eight weeks. In distinction, QUICKI (P = 0.57), HOMA-IR (P = 0.60), and serum insulin (P = 0.55) weren’t affected following Zn supplementation in comparability with patients receiving placebo. Zn sulfate supplementation seems to have favorable results on serum copeptin and hs-CRP, FBG, and renal operate in Zn-deficient DHPs. Iranian Registry of Clinical Trials Identifier: IRCT20190806044461N1.

Histopathological examination of newly-developed adhesive silicone denture relining material.

Histopathological examination of newly-developed adhesive silicone denture relining material.

We aimed to guage the subcutaneous tissue response to a newly developed adhesive silicone denture relining materials, SG, (Neo Dental Chemical Products Co., Ltd. Tokyo, Japan). We embedded the experimental materials SG and one other present management materials, Roeko Seal (RS), within the dorsal space of 22 male ddY mice.

One week and 12 weeks after the embedding, the tissues surrounding the embedded supplies had been eliminated and a histopathological examination was carried out. The outcomes reveal that the essential histopathological elements are the formation of granulation tissue and the change of the tissue to fibrous capsule over time.

The outcomes means that the newly-developed SG is secure as in contrast with the management RS, whose composition is comparable.

Histopathological examination of newly-developed adhesive silicone denture relining material.
Histopathological examination of newly-developed adhesive silicone denture relining materials.

Collaborative research on fifteen compounds within the rat-liver Comet assay built-in into 2- and 4-week repeat-dose research.

A collaborative trial was carried out to guage the likelihood of integrating the rat-liver Comet assay into repeat-dose toxicity research. Fourteen laboratories from Europe, Japan and the USA examined fifteen chemical compounds.

Two chemical compounds had been beforehand proven to induce micronuclei in an acute protocol, however had been discovered unfavorable in a 4-week Micronucleus (MN) Assay (benzo[a]pyrene and 1,2-dimethylhydrazine; Hamada et al., 2001); 4 genotoxic rat-liver carcinogens that had been unfavorable within the MN assay in bone marrow or blood (2,6-dinitrotoluene, dimethylnitrosamine, 1,2-dibromomethane, and 2-amino-3-methylimidazo[4,5-f]quinoline); three compounds used within the ongoing JaCVAM (Japanese Center for the Validation of Alternative Methods) validation research of the acute liver Comet assay (2,4-diaminotoluene, 2,6-diaminotoluene and acrylamide); three pharmaceutical-like compounds (chlordiazepoxide, pyrimethamine and gemifloxacin), and three non-genotoxic rodent liver carcinogens (methapyrilene, clofibrate and phenobarbital). Male rats obtained oral administrations of the take a look at compounds, each day for 2 or 4 weeks.

anti-EDEM2

YF-PA19810 100 ug
EUR 403
Description: Rabbit polyclonal to EDEM2

EDEM2 Antibody

6633-100
EUR 349

EDEM2 Antibody

6633-30T
EUR 146

EDEM2 Antibody

DF9503 200ul
EUR 304
Description: EDEM2 Antibody detects endogenous levels of total EDEM2.

EDEM2 Antibody

1-CSB-PA030228
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000

EDEM2 Antibody

1-CSB-PA861146LA01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

pOTB7-EDEM2

PVT18710 2 ug
EUR 231

EDEM2 siRNA

20-abx914951
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

EDEM2 Antibody

40055-100ul 100ul
EUR 390

EDEM2 Antibody

46557-100ul 100ul
EUR 252

Anti-EDEM2 (2E4)

YF-MA11569 100 ug
EUR 363
Description: Mouse monoclonal to EDEM2

EDEM2 Blocking Peptide

6633BP-50
EUR 153

EDEM2 Blocking Peptide

DF9503-BP 1mg
EUR 195

Anti-EDEM2 antibody

PAab02632 100 ug
EUR 355

EDEM2 cloning plasmid

CSB-CL861146HU-10ug 10ug
EUR 376
Description: A cloning plasmid for the EDEM2 gene.

EDEM2 Polyclonal Antibody

ES6755-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against EDEM2 from Human. This antibody is tested and validated for IHC, WB, ELISA

EDEM2 Polyclonal Antibody

ES6755-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against EDEM2 from Human. This antibody is tested and validated for IHC, WB, ELISA

EDEM2 Polyclonal Antibody

A58890 100 µg
EUR 570.55
Description: kits suitable for this type of research

EDEM2 Polyclonal Antibody

ABP55756-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

EDEM2 Polyclonal Antibody

ABP55756-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

EDEM2 Polyclonal Antibody

ABP55756-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

Anti-EDEM2 antibody

STJ92823 200 µl
EUR 197
Description: Rabbit polyclonal to EDEM2.

Polyclonal EDEM2 Antibody

AMM07003G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human EDEM2 . This antibody is tested and proven to work in the following applications:

anti- EDEM2 antibody

FNab02632 100µg
EUR 505.25
Description: Antibody raised against EDEM2

EDEM2 Conjugated Antibody

C46557 100ul
EUR 397

EDEM2 ELISA KIT|Human

EF009290 96 Tests
EUR 689

EDEM2 Antibody, HRP conjugated

1-CSB-PA861146LB01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

EDEM2 Antibody, FITC conjugated

1-CSB-PA861146LC01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

EDEM2 Antibody, Biotin conjugated

1-CSB-PA861146LD01HU
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

Human EDEM2 ELISA KIT

ELI-32317h 96 Tests
EUR 824

EDEM2 Recombinant Protein (Human)

RP010159 100 ug Ask for price

EDEM2 Recombinant Protein (Rat)

RP199049 100 ug Ask for price

EDEM2 Recombinant Protein (Mouse)

RP130856 100 ug Ask for price

Human EDEM2 shRNA Plasmid

20-abx960878
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg

Edem2 ORF Vector (Rat) (pORF)

ORF066351 1.0 ug DNA
EUR 506

EDEM2 ORF Vector (Human) (pORF)

ORF003387 1.0 ug DNA
EUR 95

Edem2 ORF Vector (Mouse) (pORF)

ORF043620 1.0 ug DNA
EUR 506

EDEM2 Polyclonal Antibody, Biotin Conjugated

A58891 100 µg
EUR 570.55
Description: fast delivery possible

EDEM2 Polyclonal Antibody, FITC Conjugated

A58892 100 µg
EUR 570.55
Description: reagents widely cited

EDEM2 Polyclonal Antibody, HRP Conjugated

A58893 100 µg
EUR 570.55
Description: Ask the seller for details

EDEM2 sgRNA CRISPR Lentivector set (Human)

K0653501 3 x 1.0 ug
EUR 339

Edem2 sgRNA CRISPR Lentivector set (Rat)

K7428201 3 x 1.0 ug
EUR 339

Edem2 sgRNA CRISPR Lentivector set (Mouse)

K3235601 3 x 1.0 ug
EUR 339

EDEM2 3'UTR Luciferase Stable Cell Line

TU006560 1.0 ml
EUR 1394

Edem2 3'UTR GFP Stable Cell Line

TU155598 1.0 ml Ask for price

Edem2 3'UTR Luciferase Stable Cell Line

TU105598 1.0 ml Ask for price

Edem2 3'UTR Luciferase Stable Cell Line

TU203777 1.0 ml Ask for price

Edem2 3'UTR GFP Stable Cell Line

TU253777 1.0 ml Ask for price

EDEM2 3'UTR GFP Stable Cell Line

TU056560 1.0 ml
EUR 1394

EDEM2 Protein Vector (Mouse) (pPB-C-His)

PV174478 500 ng
EUR 603

EDEM2 Protein Vector (Mouse) (pPB-N-His)

PV174479 500 ng
EUR 603

EDEM2 Protein Vector (Mouse) (pPM-C-HA)

PV174480 500 ng
EUR 603

EDEM2 Protein Vector (Mouse) (pPM-C-His)

PV174481 500 ng
EUR 603

EDEM2 Protein Vector (Rat) (pPB-C-His)

PV265402 500 ng
EUR 603

EDEM2 Protein Vector (Rat) (pPB-N-His)

PV265403 500 ng
EUR 603

EDEM2 Protein Vector (Rat) (pPM-C-HA)

PV265404 500 ng
EUR 603

EDEM2 Protein Vector (Rat) (pPM-C-His)

PV265405 500 ng
EUR 603

EDEM2 Protein Vector (Human) (pPB-C-His)

PV013545 500 ng
EUR 329

EDEM2 Protein Vector (Human) (pPB-N-His)

PV013546 500 ng
EUR 329

EDEM2 Protein Vector (Human) (pPM-C-HA)

PV013547 500 ng
EUR 329

EDEM2 Protein Vector (Human) (pPM-C-His)

PV013548 500 ng
EUR 329

EDEM2 sgRNA CRISPR Lentivector (Human) (Target 1)

K0653502 1.0 ug DNA
EUR 154

EDEM2 sgRNA CRISPR Lentivector (Human) (Target 2)

K0653503 1.0 ug DNA
EUR 154

EDEM2 sgRNA CRISPR Lentivector (Human) (Target 3)

K0653504 1.0 ug DNA
EUR 154

Edem2 sgRNA CRISPR Lentivector (Rat) (Target 1)

K7428202 1.0 ug DNA
EUR 154

Edem2 sgRNA CRISPR Lentivector (Rat) (Target 2)

K7428203 1.0 ug DNA
EUR 154

Edem2 sgRNA CRISPR Lentivector (Rat) (Target 3)

K7428204 1.0 ug DNA
EUR 154

Edem2 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3235602 1.0 ug DNA
EUR 154

Edem2 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3235603 1.0 ug DNA
EUR 154

Edem2 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3235604 1.0 ug DNA
EUR 154

Monoclonal EDEM2 Antibody (clone 2E4), Clone: 2E4

AMM07004G 0.05mg
EUR 528
Description: A Monoclonal antibody against Human EDEM2 (clone 2E4). The antibodies are raised in Mouse and are from clone 2E4. This antibody is applicable in WB and IHC-P, E

EDEM2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

LV791509 1.0 ug DNA
EUR 316

EDEM2 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)

LV791510 1.0 ug DNA
EUR 316

EDEM2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV650983 1.0 ug DNA
EUR 682

EDEM2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV650987 1.0 ug DNA
EUR 682

EDEM2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV650988 1.0 ug DNA
EUR 682

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody

abx036086-100ug 100 ug
EUR 391

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody

20-abx310614
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

ER Degradation Enhancer, Mannosidase alpha-Like 2 (EDEM2) Antibody

20-abx322885
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody

abx232632-100ug 100 ug
EUR 481

EDEM2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K0653505 3 x 1.0 ug
EUR 376

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K7428205 3 x 1.0 ug
EUR 376

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3235605 3 x 1.0 ug
EUR 376

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody (HRP)

20-abx310615
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody (FITC)

20-abx310616
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

ER Degradation Enhancer, Mannosidase Alpha-Like 2 (EDEM2) Antibody (Biotin)

20-abx310617
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

EDEM2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV791507 1.0 ug DNA
EUR 374

EDEM2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV791508 1.0 ug DNA
EUR 374

EDEM2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K0653506 1.0 ug DNA
EUR 167

EDEM2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K0653507 1.0 ug DNA
EUR 167

EDEM2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K0653508 1.0 ug DNA
EUR 167

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K7428206 1.0 ug DNA
EUR 167

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K7428207 1.0 ug DNA
EUR 167

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K7428208 1.0 ug DNA
EUR 167

EDEM2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV650984 1.0 ug DNA
EUR 682

EDEM2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV650985 1.0 ug DNA
EUR 740

EDEM2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV650986 1.0 ug DNA
EUR 740

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3235606 1.0 ug DNA
EUR 167

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3235607 1.0 ug DNA
EUR 167

Edem2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3235608 1.0 ug DNA
EUR 167

Human ER Degradation Enhancer, Mannosidase alpha-Like 2 (EDEM2) ELISA Kit

abx387046-96tests 96 tests
EUR 911

The prime dose was meant to be the very best dose producing scientific indicators or histopathological results with out inflicting mortality, i.e. the 28-day most tolerated dose. The liver Comet assay was carried out in accordance with revealed suggestions and following the protocol for the continuing JaCVAM validation trial. Laboratories supplied liver Comet assay knowledge obtained on the finish of the long-term (2- or 4-week) research along with an analysis of liver histology.

Most of the take a look at compounds had been additionally investigated within the liver Comet assay after short-term (1-Three each day) administration to match the sensitivity of the 2 research designs. MN analyses had been carried out in bone marrow or peripheral blood for many of the compounds to find out whether or not the liver Comet assay might complement the MN assay for the detection of genotoxins after long-term therapy.

Most of the liver genotoxins had been optimistic and the three non-genotoxic carcinogens gave unfavorable end result within the liver Comet assay after long-term administration. There was a excessive concordance between short- and long-term Comet assay outcomes. Most compounds when examined as much as the utmost tolerated dose had been accurately detected in each short- and long-term research.

Discrepant outcomes had been obtained with 2,6 diaminotoluene (unfavorable within the short-term, however optimistic within the long-term research), phenobarbital (optimistic within the short-term, however unfavorable within the long-term research) and gemifloxacin (optimistic within the short-term, however unfavorable within the long-term research).

The total outcomes point out that the liver Comet assay will be built-in inside repeat-dose toxicity research and effectively enhances the MN assay in detecting genotoxins. Practical elements of integrating genotoxicity endpoints into repeat-dose research had been evaluated, e.g. by investigating the impact of blood sampling, as usually carried out throughout toxicity research, on the Comet and MN assays.

The bleeding protocols used right here didn’t have an effect on the conclusions of the Comet assay or of the MN assays in blood and bone marrow. Although bleeding typically elevated reticulocyte frequencies, the sensitivity of the response within the MN assay was not altered. 

FLX pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminaran on rat cecal microbiotas.

FLX pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminaran on rat cecal microbiotas.

Edible brown algae are used as main meals materials in Far East Asian international locations, significantly in South Korea and Japan. They comprise fermentable dietary fibers, alginic acid (uronic acid polymer) and laminaran (β-1,3-glucan), which can be fermented into natural acids by intestinal micro organism.

To make clear the impact of edible algae on the intestinal setting, the cecal microbiotas of rats fed diets containing no dietary fiber (management) or 2% (wt/wt) sodium alginate or laminaran for two weeks have been analyzed utilizing FLX amplicon pyrosequencing with bar-coded primers focusing on the bacterial 16S rRNA gene. The most considerable phylum in all teams was Firmicutes.

Specifically, Allobaculum was dominant in all food regimen teams. In addition, Bacteroides capillosus (37.1%) was considerable in the alginate group, whereas Clostridium ramosum (3.14%) and Parabacteroides distasonis (1.36%) have been solely detected in the laminaran group. Furthermore, rats fed alginate confirmed simplified microbiota phylotypes in contrast with others. With respect to cecal chemical compounds, laminaran increased cecal natural acid ranges, significantly propionic acid. Alginate elevated complete cecal natural acids.

Cecal putrefactive compounds, comparable to indole, H(2)S, and phenol, have been decreased by each alginate and laminaran. These outcomes point out that edible brown algae can alter the intestinal setting, with fermentation by intestinal microbiota.

FLX pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminaran on rat cecal microbiotas.
FLX pyrosequencing analysis of the effects of the brown-algal fermentable polysaccharides alginate and laminaran on rat cecal microbiotas.

Tsunami lung.

We encountered three instances of lung issues attributable to drowning in the current massive tsunami that struck following the Great East Japan Earthquake. All three have been females, and two of them have been outdated aged. All segments of each lungs have been concerned in all the three sufferers, necessitating ICU admission and endotracheal intubation and mechanical air flow. All three died inside 3 weeks.

EDEM3 siRNA

20-abx914952
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

EDEM3 siRNA

20-abx914953
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

EDEM3 Antibody

45972-100ul 100ul
EUR 252

EDEM3 Antibody

45972-50ul 50ul
EUR 187

EDEM3 Blocking Peptide

3614BP-50
EUR 153

EDEM3 Blocking Peptide

DF9504-BP 1mg
EUR 195

EDEM3 cloning plasmid

CSB-CL863170HU-10ug 10ug
EUR 233
Description: A cloning plasmid for the EDEM3 gene.

EDEM3 Polyclonal Antibody

ES9649-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against EDEM3 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

EDEM3 Polyclonal Antibody

ES9649-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against EDEM3 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

EDEM3 Polyclonal Antibody

ABP58454-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of EDEM3 from Human, Mouse. This EDEM3 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human EDEM3 protein

EDEM3 Polyclonal Antibody

ABP58454-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of EDEM3 from Human, Mouse. This EDEM3 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human EDEM3 protein

EDEM3 Polyclonal Antibody

ABP58454-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of EDEM3 from Human, Mouse. This EDEM3 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human EDEM3 protein

Anti-EDEM3 antibody

STJ190807 200 µl
EUR 197
Description: Unconjugated Rabbit polyclonal to EDEM3

Polyclonal EDEM3 Antibody

AMM07005G 0.1mg
EUR 528
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human EDEM3 . This antibody is tested and proven to work in the following applications:

EDEM3 Conjugated Antibody

C45972 100ul
EUR 397

Mouse Edem3 ELISA KIT

ELI-26645m 96 Tests
EUR 865

Human EDEM3 ELISA KIT

ELI-47172h 96 Tests
EUR 824

Mouse EDEM3 shRNA Plasmid

20-abx975889
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg

Human EDEM3 shRNA Plasmid

20-abx962830
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg

Edem3 ORF Vector (Rat) (pORF)

ORF066352 1.0 ug DNA
EUR 506

EDEM3 ORF Vector (Human) (pORF)

ORF003388 1.0 ug DNA
EUR 95

Edem3 ORF Vector (Mouse) (pORF)

ORF043621 1.0 ug DNA
EUR 506

EDEM3 sgRNA CRISPR Lentivector set (Human)

K0653601 3 x 1.0 ug
EUR 339

Edem3 sgRNA CRISPR Lentivector set (Rat)

K6190401 3 x 1.0 ug
EUR 339

Edem3 sgRNA CRISPR Lentivector set (Mouse)

K3468201 3 x 1.0 ug
EUR 339

EDEM3 3'UTR Luciferase Stable Cell Line

TU006561 1.0 ml
EUR 2333

Edem3 3'UTR GFP Stable Cell Line

TU155599 1.0 ml Ask for price

Edem3 3'UTR Luciferase Stable Cell Line

TU105599 1.0 ml Ask for price

Edem3 3'UTR Luciferase Stable Cell Line

TU203778 1.0 ml Ask for price

Edem3 3'UTR GFP Stable Cell Line

TU253778 1.0 ml Ask for price

EDEM3 3'UTR GFP Stable Cell Line

TU056561 1.0 ml
EUR 2333

EDEM3 Protein Vector (Mouse) (pPB-C-His)

PV174482 500 ng
EUR 1065

EDEM3 Protein Vector (Mouse) (pPB-N-His)

PV174483 500 ng
EUR 1065

EDEM3 Protein Vector (Mouse) (pPM-C-HA)

PV174484 500 ng
EUR 1065

EDEM3 Protein Vector (Mouse) (pPM-C-His)

PV174485 500 ng
EUR 1065

EDEM3 Protein Vector (Rat) (pPB-C-His)

PV265406 500 ng
EUR 1166

EDEM3 Protein Vector (Rat) (pPB-N-His)

PV265407 500 ng
EUR 1166

EDEM3 Protein Vector (Rat) (pPM-C-HA)

PV265408 500 ng
EUR 1166

EDEM3 Protein Vector (Rat) (pPM-C-His)

PV265409 500 ng
EUR 1166

EDEM3 Protein Vector (Human) (pPB-C-His)

PV013549 500 ng
EUR 329

EDEM3 Protein Vector (Human) (pPB-N-His)

PV013550 500 ng
EUR 329

EDEM3 Protein Vector (Human) (pPM-C-HA)

PV013551 500 ng
EUR 329

EDEM3 Protein Vector (Human) (pPM-C-His)

PV013552 500 ng
EUR 329

EDEM3 sgRNA CRISPR Lentivector (Human) (Target 1)

K0653602 1.0 ug DNA
EUR 154

EDEM3 sgRNA CRISPR Lentivector (Human) (Target 2)

K0653603 1.0 ug DNA
EUR 154

EDEM3 sgRNA CRISPR Lentivector (Human) (Target 3)

K0653604 1.0 ug DNA
EUR 154

Edem3 sgRNA CRISPR Lentivector (Rat) (Target 1)

K6190402 1.0 ug DNA
EUR 154

Edem3 sgRNA CRISPR Lentivector (Rat) (Target 2)

K6190403 1.0 ug DNA
EUR 154

Edem3 sgRNA CRISPR Lentivector (Rat) (Target 3)

K6190404 1.0 ug DNA
EUR 154

Edem3 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3468202 1.0 ug DNA
EUR 154

Edem3 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3468203 1.0 ug DNA
EUR 154

Edem3 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3468204 1.0 ug DNA
EUR 154

EDEM3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K0653605 3 x 1.0 ug
EUR 376

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K6190405 3 x 1.0 ug
EUR 376

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K3468205 3 x 1.0 ug
EUR 376

ER Degradation-Enhancing Alpha-Mannosidase-Like Protein 3 (EDEM3) Antibody

abx028901-400ul 400 ul
EUR 523

ER Degradation-Enhancing Alpha-Mannosidase-Like Protein 3 (EDEM3) Antibody

abx028901-80l 80 µl
EUR 286

ER Degradation-Enhancing Alpha-Mannosidase-Like Protein 3 (EDEM3) Antibody

20-abx215068
  • EUR 425.00
  • EUR 342.00
  • 100 ug
  • 50 ug

EDEM3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K0653606 1.0 ug DNA
EUR 167

EDEM3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K0653607 1.0 ug DNA
EUR 167

EDEM3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K0653608 1.0 ug DNA
EUR 167

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K6190406 1.0 ug DNA
EUR 167

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K6190407 1.0 ug DNA
EUR 167

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K6190408 1.0 ug DNA
EUR 167

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K3468206 1.0 ug DNA
EUR 167

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K3468207 1.0 ug DNA
EUR 167

Edem3 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K3468208 1.0 ug DNA
EUR 167

In no less than two instances, misswallowing of oil was suspected from the options famous at the time of the detection. Sputum tradition for micro organism yielded isolation of Stenotrophomonas maltophilia, Legionella pneumophila, Burkholderia cepacia, and Pseudomonas aeruginosa. The trigger of tsunami lung could also be a mix of chemical induced pneumonia and bacterial pneumonia.

Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity.

OBJECTIVE
To assess the medical efficacy of cultivated oral mucosal epithelial transplantation (COMET) for the remedy of persistent epithelial defect (PED).
METHODS
We handled 10 eyes of 9 sufferers with PED (Stevens-Johnson syndrome: three eyes; thermal/chemical harm: 5 eyes; ocular cicatricial pemphigoid: two eyes) with COMET at Kyoto Prefectural University of Medicine, Kyoto, Japan from 2002 to 2008.
RESULTS
Preoperatively, PED existed on over greater than 50% of the corneal surface in seven eyes. Severe ocular surface irritation with fibrovascular tissue surrounded the PED in all 10 eyes. At 24-weeks postoperative, PED had improved in all instances besides 1 in which the affected person was unable to return to the hospital (95% CI, 55.5-99.7; Wilcoxon signed-rank check, p = 0.0078).
The preoperative median of logarithmic minimal angle of decision was 1.85 (vary 0.15-2.70), and 1.85, 1.85, and 1.52 on the 4th, 12th, and 24th postoperative week, respectively.
The imply whole preoperative ocular surface grading rating was 7.0 (vary 4-17). At Four and 12 weeks postoperative, the whole ocular surface grading rating had improved considerably (p = 0.0020, p = 0.0078), and at 24 weeks postoperative, it was 3.0 (vary 2-12, p = 0.0234). During the follow-up interval (median 23.Three months, vary 5.6-39.7 months), no recurrence of PED was noticed in any eye, and long-term ocular surface stability was obtained.
CONCLUSIONS
COMET enabled full epithelialization of PED and stabilization of the ocular surface in sufferers with severe ocular surface illness, thus stopping end-stage cicatrization and imaginative and prescient loss at a later stage.
 Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity.
Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory exercise.

Antianxiety-like results of Chimpi (dried citrus peels) in the elevated open-platform check.

Dried citrus peels (Chimpi) is likely one of the most typical pure medicines with qi (power circulate) rectifying and shi (dampness) drying actions, which originates from Citrus unshiu, and/or C. reticulata in response to the definition of the pharmacopoeiae of Japan and China. In this examine, the pharmacological results of their extracts and main chemical constituents hesperidin and its aglycone hesperetin on nervousness had been examined with an nervousness mannequin of elevated open-platform check utilizing ICR male mice (6-week-old) and whole period of freezing was decreased in fluoxetine-treated mice, which is a straightforward and extremely delicate to the consequences of serotonergic anxiolytics.

EDTA disodium salt dihydrate

GE3023-100G 100 g
EUR 40

EDTA disodium salt dihydrate

GE3023-1KG 1 kg
EUR 70

EDTA disodium salt dihydrate

GE3023-250G 250 g
EUR 46

EDTA disodium salt dihydrate

GE3023-500G 500 g
EUR 54

EDTA disodium salt dihydrate

GE3023-5KG 5 kg
EUR 150

EDTA, disodium salt, dihydrate

EB0185 500g
EUR 70.01

EDTA magnesium disodium salt hydrate

GE3956-100G 100 g
EUR 66

EDTA magnesium disodium salt hydrate

GE3956-1KG 1 kg
EUR 245

EDTA magnesium disodium salt hydrate

GE3956-250G 250 g
EUR 102

EDTA magnesium disodium salt hydrate

GE3956-25G 25 g
EUR 45

EDTA magnesium disodium salt hydrate

GE3956-500G 500 g
EUR 154

EDTA disodium zinc salt hydrate

GX3802-100G 100 g
EUR 54

EDTA disodium zinc salt hydrate

GX3802-250G 250 g
EUR 75

EDTA disodium zinc salt hydrate

GX3802-25G 25 g
EUR 43

EDTA disodium zinc salt hydrate

GX3802-500G 500 g
EUR 110

EDTA manganese disodium salt hydrate

GX6009-100G 100 g
EUR 102

EDTA manganese disodium salt hydrate

GX6009-250G 250 g
EUR 174

EDTA manganese disodium salt hydrate

GX6009-25G 25 g
EUR 58

EDTA manganese disodium salt hydrate

GX6009-500G 500 g
EUR 269

EDTA disodium and monocalcium salt

EK014P2 500g
EUR 96.11

EDTA copper(II) disodium salt

EB0434 250g
EUR 83.93

EDTA disodium and monomagnesium salt

EB0435 500g
EUR 110.9

EDTA zinc (II), disodium salt

EB6666 100g
EUR 64.79

cGAMP disodium salt

2435-100
EUR 196

NADH, disodium salt

2735-1000
EUR 169

NADH, disodium salt

2735-500
EUR 142

NADH, disodium salt

2735-5000
EUR 544

NADP, disodium salt

2736-100
EUR 153

NADP, disodium salt

2736-1000
EUR 784

NADP, disodium salt

2736-500
EUR 457

NBQX disodium salt

2759-25
EUR 642

NBQX disodium salt

2759-5
EUR 207

BCA disodium salt

2810-100G
EUR 865

BCA disodium salt

2810-1G
EUR 120

BCA disodium salt

2810-500G
EUR 2605

BCA disodium salt

2810-5G
EUR 218

Hypoxanthine Disodium Salt

B1185-1G
EUR 109

Hypoxanthine Disodium Salt

B1185-5G
EUR 240

BCIP disodium salt

BB1171 500mg
EUR 232.7

ADA disodium salt

GB0256-100G 100 g
EUR 110

PIPES disodium salt

GB1799-100G 100 g
EUR 110

ADA disodium salt

GB0256-500G 500 g
EUR 341

PIPES disodium salt

GB1799-250G 250 g
EUR 181

PIPES disodium salt

GB1799-25G 25 g
EUR 70

PIPES disodium salt

GB1799-500G 500 g
EUR 309

POPSO disodium salt

GB6170-100G 100 g
EUR 269

POPSO disodium salt

GB6170-25G 25 g
EUR 126

Carbenicillin disodium salt

GA1299-10G 10 g
EUR 229

Carbenicillin disodium salt

GA1299-1G 1 g
EUR 86

Carbenicillin disodium salt

GA1299-250MG 250 mg
EUR 59

Carbenicillin disodium salt

GA1299-25G 25 g
EUR 341

Carbenicillin disodium salt

GA1299-5G 5 g
EUR 158

Ticarcillin disodium salt

GA1874-100MG 100 mg
EUR 50

Ticarcillin disodium salt

GA1874-1G 1 g
EUR 110

Ticarcillin disodium salt

GA1874-500MG 500 mg
EUR 78

Cefotetan disodium salt

GA5476-100MG 100 mg
EUR 86

Cefotetan disodium salt

GA5476-1G 1 g
EUR 181

Phosphomycin disodium salt

GA7173-1G 1 g
EUR 70

Phosphomycin disodium salt

GA7173-25G 25 g
EUR 289

Phosphomycin disodium salt

GA7173-5G 5 g
EUR 134

cGAMP disodium salt

GL2101-100UG 100 ug
EUR 160

cGAMP disodium salt

GL2101-500UG 500 ug
EUR 332

Balsalazide disodium salt

GP7647-1G 1 g
EUR 110

Etidronate disodium salt

GP3560-1G 1 g
EUR 174

Lobenzarit disodium salt

GP3753-100MG 100 mg
EUR 229

ATP (disodium salt)

HY-B0345A 10mM/1mL
EUR 113

Methoxatin (disodium salt)

HY-100196A 10mM/1mL
EUR 186

Fluorescein, disodium salt

FB0203 100g
EUR 63.92

POPSO, disodium salt

PB4959 25g
EUR 76.97

NADH (disodium salt)

HY-F0001 10mM/1mL
EUR 113

NADP (disodium salt)

HY-F0002A 500mg
EUR 271

Dimethylglyoxime disodium salt

DD1221 100g
EUR 63.92

Carbenicillin, Disodium Salt

A2511-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: Carbenicillin inhibits the cell-wall synthesis (peptidoglycan cross-linking) by inactivating transpeptidase on the inner surface of the bacterial cell membrane.Carbenicillin is a white to slightly yellow, hygroscopic powder soluble in water and in alcohol.

Carbenicillin, Disodium Salt

A2511-50 50 mg
EUR 131
Description: Carbenicillin inhibits the cell-wall synthesis (peptidoglycan cross-linking) by inactivating transpeptidase on the inner surface of the bacterial cell membrane.Carbenicillin is a white to slightly yellow, hygroscopic powder soluble in water and in alcohol.

UDP disodium salt

B7278-5.1 10 mM (in 1mL DMSO)
EUR 108

UDP disodium salt

B7278-50 50 mg
EUR 125

Phosphocreatine disodium salt

B7648-25 25 mg
EUR 196

ATP disodium salt

B3304-5.1 10 mM (in 1mL H2O)
EUR 108
Description: ATP Disodium salt is a P2 purinoceptor agonist.

ATP disodium salt

B3304-50 50 mg
EUR 128
Description: ATP Disodium salt is a P2 purinoceptor agonist.

ATP disodium salt

B3304-S Evaluation Sample
EUR 81
Description: ATP Disodium salt is a P2 purinoceptor agonist.

Phosphoramidon Disodium Salt

B4790-25 25 mg
EUR 490
Description: Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1]. Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.

Phosphoramidon Disodium Salt

B4790-5 5 mg
EUR 189
Description: Phosphoramidon Disodium Salt is a potent inhibitor of metalloproteinase [1]. Metalloproteinase is an enzyme whose catalytic mechanism involves a metal. Most metalloproteases require zinc and some require cobalt.

DNQX disodium salt

B5288-100 100 mg
EUR 279

DNQX disodium salt

B5288-25 25 mg
EUR 128

DNQX disodium salt

B5288-50 50 mg
EUR 186

NBQX disodium salt

B6566-10 10 mg
EUR 222

NBQX disodium salt

B6566-25 25 mg
EUR 389

NBQX disodium salt

B6566-5 5 mg
EUR 139

NBQX disodium salt

B6566-50 50 mg
EUR 683

CNQX disodium salt

B6567-1 1 mg
EUR 134

CNQX disodium salt

B6567-10 10 mg
EUR 215

CNQX disodium salt

B6567-50 50 mg
EUR 746

EDTA calcium disodium salt dihydrate, BP, Ph. Eur., USP grade

GE8581-1KG 1 kg
EUR 201

EDTA calcium disodium salt dihydrate, BP, Ph. Eur., USP grade

GE8581-250G 250 g
EUR 86

EDTA calcium disodium salt dihydrate, BP, Ph. Eur., USP grade

GE8581-500G 500 g
EUR 126

EDTA tetrasodium salt hydrate

GE3450-1KG 1 kg
EUR 68

EDTA tetrasodium salt hydrate

GE3450-500G 500 g
EUR 53

EDTA tetrasodium salt hydrate

GE3450-5KG 5 kg
EUR 166

EDTA dipotassium salt dihydrate

GE5635-100G 100 g
EUR 54

EDTA dipotassium salt dihydrate

GE5635-250G 250 g
EUR 74

EDTA dipotassium salt dihydrate

GE5635-500G 500 g
EUR 102

EDTA ferric sodium salt

GE7700-100G 100 g
EUR 44

EDTA ferric sodium salt

GE7700-1KG 1 kg
EUR 98

EDTA ferric sodium salt

GE7700-250G 250 g
EUR 54

EDTA ferric sodium salt

GE7700-500G 500 g
EUR 70

EDTA tetrasodium salt hydrate

GE3450-100G 100 g
EUR 41

EDTA tetrasodium salt hydrate

GE3450-250G 250 g
EUR 45

EDTA trisodium salt dihydrate

GE9701-100G 100 g
EUR 54

EDTA trisodium salt dihydrate

GE9701-250G 250 g
EUR 78

EDTA trisodium salt dihydrate

GE9701-500G 500 g
EUR 118

EDTA tetrasodium salt dihydrate

GK0795-100G 100 g
EUR 40

EDTA tetrasodium salt dihydrate

GK0795-1KG 1 kg
EUR 70

EDTA tetrasodium salt dihydrate

GK0795-2500G 2500 g
EUR 118

EDTA tetrasodium salt dihydrate

GK0795-250G 250 g
EUR 46

EDTA tetrasodium salt dihydrate

GK0795-500G 500 g
EUR 53

EDTA tripotassium salt dihydrate

GL1464-100G 100 g
EUR 61

EDTA tripotassium salt dihydrate

GL1464-250G 250 g
EUR 86

EDTA tripotassium salt dihydrate

GL1464-25G 25 g
EUR 44

EDTA tripotassium salt dihydrate

GL1464-500G 500 g
EUR 128

EDTA, dipotassium salt, dihydrate

ED0075 250g
EUR 83.06

EDTA, tetrasodium salt dihydrate

EB0436 500g
EUR 88.28

ADA buffer, disodium salt

AB0005 25g
EUR 66.53

Pamoic acid disodium salt

GK6564-100G 100 g
EUR 86

Pamoic acid disodium salt

GK6564-250G 250 g
EUR 142

Pamoic acid disodium salt

GK6564-25G 25 g
EUR 54

Sulfobromophthalein disodium salt hydrate

GK6995-25G 25 g
EUR 245

Sulfobromophthalein disodium salt hydrate

GK6995-5G 5 g
EUR 110

Clodronate disodium salt hydrate

GP6103-1G 1 g
EUR 86

Bathocuproinedisulfonic acid disodium salt

GT0734-100MG 100 mg
EUR 50

Bathocuproinedisulfonic acid disodium salt

GT0734-1G 1 g
EUR 110

Bathocuproinedisulfonic acid disodium salt

GT0734-250MG 250 mg
EUR 62

Bathocuproinedisulfonic acid disodium salt

GT0734-500MG 500 mg
EUR 80

MUP, disodium salt, trihydrate

M0740 1g
EUR 93.5

UDP-GlcNAc Disodium Salt

HY-112174 5mg
EUR 165

(RS)-MCPG disodium salt

B7476-10 10 mg
EUR 302

(RS)-MCPG disodium salt

B7476-50 50 mg
EUR 1114

Pamoic acid disodium salt

B7638-10 10 mg
EUR 480

Pamoic acid disodium salt

B7638-50 50 mg
EUR 1861

CL 316243 disodium salt

B6766-1 1 mg
EUR 109
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

CL 316243 disodium salt

B6766-10 10 mg
EUR 293
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

CL 316243 disodium salt

B6766-5 5 mg
EUR 206
Description: EC50: (3.0±0.3) X 10-8 M for ?3 adrenoceptor [1].Benzodioxole-containing phenethanolamine CL-316,243 is a murine-selective ?3 adrenoceptor agonist which can correct obesity and elevated blood glucose in diabetic rodents.

EDTA, Iron (III), sodium salt

EB0437 100g
EUR 65.66

MUP, disodium salt [4-Methylumbelliferyl phosphate, disodium salt] *CAS 22919-26-2*

11610 25 mg
EUR 115

MUP, disodium salt [4-Methylumbelliferyl phosphate, disodium salt] *CAS 22919-26-2*

11612 10 g
EUR 898

L-?-Hydroxyglutaric Acid Disodium Salt

B2812-25
EUR 349

L-?-Hydroxyglutaric Acid Disodium Salt

B2812-5
EUR 131

Chromotropic Acid Disodium Salt Dihydrate

20-abx186412
  • EUR 328.00
  • EUR 230.00
  • 100 g
  • 25 g

Creatine phosphate, disodium salt, Tetrahydrate

CB0128 5g
EUR 70.88

BCA (Bicinchoninic acid), disodium salt

BB0260 5g
EUR 154.4

Guanosine 5'-triphosphate disodium salt

20-abx180774
  • EUR 300.00
  • EUR 565.00
  • 1 g
  • 5 g

4-Methylumbelliferyl phosphate disodium salt

GC5745-1G 1 g
EUR 166

4-Methylumbelliferyl phosphate disodium salt

GC5745-250MG 250 mg
EUR 75

Uridine 5'-diphosphate disodium salt

GC9934-100MG 100 mg
EUR 74

Uridine 5'-diphosphate disodium salt

GC9934-1G 1 g
EUR 261

Uridine 5'-diphosphate disodium salt

GC9934-250MG 250 mg
EUR 110

Uridine 5'-diphosphate disodium salt

GC9934-25MG 25 mg
EUR 52

Uridine 5'-diphosphate disodium salt

GC9934-500MG 500 mg
EUR 162

Phenyl phosphate disodium salt dihydrate

GE1672-50G 50 g
EUR 99

Guanosine 5'-diphosphate disodium salt

GE3702-100MG 100 mg
EUR 118

Guanosine 5'-diphosphate disodium salt

GE3702-250MG 250 mg
EUR 174

Adenosine 5'-diphosphate disodium salt

GE3988-1G 1 g
EUR 78

Adenosine 5'-diphosphate disodium salt

GE3988-250MG 250 mg
EUR 50

L-Tyrosine disodium salt hydrate

GE4061-100G 100 g
EUR 84

L-Tyrosine disodium salt hydrate

GE4061-25G 25 g
EUR 48

L-Tyrosine disodium salt hydrate

GE4061-50G 50 g
EUR 61

Uridine 5'-monophosphate disodium salt

GE7138-100G 100 g
EUR 269

Uridine 5'-monophosphate disodium salt

GE7138-25G 25 g
EUR 110

Uridine 5'-monophosphate disodium salt

GE7138-5G 5 g
EUR 62

Creatine phosphate disodium salt hydrate

GE7721-100G 100 g
EUR 333

Creatine phosphate disodium salt hydrate

GE7721-25G 25 g
EUR 150

Creatine phosphate disodium salt hydrate

GE7721-5G 5 g
EUR 74

Phenyl phosphate disodium salt dihydrate

GE1672-100G 100 g
EUR 150

Phenyl phosphate disodium salt dihydrate

GE1672-10G 10 g
EUR 52

Phenyl phosphate disodium salt dihydrate

GE1672-25G 25 g
EUR 74

Guanosine-5'-triphosphate disodium salt

GE2026-1G 1 g
EUR 229

Ceftriaxone disodium salt hemi(heptahydrate)

GA6812-1G 1 g
EUR 62

Ceftriaxone disodium salt hemi(heptahydrate)

GA6812-25G 25 g
EUR 229

Ceftriaxone disodium salt hemi(heptahydrate)

GA6812-5G 5 g
EUR 94

Bicinchoninic acid disodium salt hydrate

GK3616-10G 10 g
EUR 134

Bicinchoninic acid disodium salt hydrate

GK3616-1G 1 g
EUR 54

Bicinchoninic acid disodium salt hydrate

GK3616-25G 25 g
EUR 240

Bicinchoninic acid disodium salt hydrate

GK3616-5G 5 g
EUR 90

Succinic acid disodium salt, anhydrous

GK7702-100G 100 g
EUR 43

Succinic acid disodium salt, anhydrous

GK7702-1KG 1 kg
EUR 94

Succinic acid disodium salt, anhydrous

GK7702-5KG 5 kg
EUR 245

Dexamethasone 21-phosphate disodium salt

GL6086-1G 1 g
EUR 110

Dexamethasone 21-phosphate disodium salt

GL6086-5G 5 g
EUR 269

Succinic acid disodium salt, anhydrous

GK7702-250G 250 g
EUR 52

Succinic acid disodium salt, anhydrous

GK7702-500G 500 g
EUR 66

Xanthosine 5'-monophosphate disodium salt

GN2077-100MG 100 mg
EUR 229

Moreover, yokukansankachimpihange (YKH), a mix of yokukansan with Chimpi and Hange (Pinellia) was additionally examined as a result of Chimpi is taken into account to play an important half in this formulation in opposition to anxious signs in dementia sufferers.

The outcomes confirmed that Chimpi and YKH possess a major anxiolytic-like impact much like that of fluoxetine, suggesting that they could be much like fluoxetine in their pharmacological actions by way of the serotonergic neurotransmission pathway.

Moreover, it additionally advised that the main chemical constituent, hesperidin may very well be an lively precept attributed to the antianxiety-like results with a direct and oblique position through its aglycone hesperetin.